Steve OLoughlin - Actinium Pharmaceuticals Principal Financial and Accounting Officer
| ATNM Stock | USD 7.17 0.32 4.67% |
Executive
Mr. Steve OLoughlin is a Principal Financial and Accounting Officer of the Company. Steve OLoughlin was our Principal Financial Officer since May 2017. Mr. OLoughlin joined Actinium in October 2015 as Vice President, Finance and Corporationrationrate Development, with almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Mr. OLoughlin worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. OLoughlin held the position of Vice President, Corporationrationrate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. Previously, From June 2010 to June 2012, Mr. OLoughlin held corporate development positions with Caliber I.D., a publicly traded diagnostics company. Mr. OLoughlin previously worked in investment banking at Jesup Lamont where he focused on the biotechnology and life sciences industries since 2017.
| Age | 32 |
| Tenure | 7 years |
| Address | 100 Park Avenue, New York, NY, United States, 10017 |
| Phone | 646 677 3870 |
| Web | https://www.actiniumpharma.com |
Actinium Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3317) % which means that it has lost $0.3317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9492) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 23rd of April 2024, Total Current Assets is likely to grow to about 82.2 M, though Non Currrent Assets Other are likely to grow to (0.95).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Friso Postma | BioXcel Therapeutics | N/A | |
| Stephanie Diaz | Viking Therapeutics | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Prathyusha Durabaibu | Sangamo Therapeutics | 39 | |
| Phillip Ramsey | Sangamo Therapeutics | N/A | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| William MD | Exelixis | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Bernhard MBA | Ocuphire Pharma | 68 | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Ulrich Grau | Affimed NV | 64 | |
| Lisa MD | Sangamo Therapeutics | 58 | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Rochelle Hanley | Viking Therapeutics | 61 | |
| Lori MBA | Axsome Therapeutics | 46 | |
| Tarek Sallam | Rigel Pharmaceuticals | N/A | |
| RN MBA | Transcode Therapeutics | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Adam Waldman | TG Therapeutics | N/A | |
| Michael Zamloot | Cassava Sciences | N/A | |
Management Performance
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.33 |
Actinium Pharmaceuticals Leadership Team
Elected by the shareholders, the Actinium Pharmaceuticals' board of directors comprises two types of representatives: Actinium Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actinium. The board's role is to monitor Actinium Pharmaceuticals' management team and ensure that shareholders' interests are well served. Actinium Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actinium Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nitya Ray, Executive Vice President Head - Product Development, Manufacturing and Supply Chain | ||
| Qing Liang, VP Sciences | ||
| Dale Ludwig, Chief Scientific Officer | ||
| Sergio Traversa, Interim CFO, Independent Director | ||
| Dragan Cicic, COO, Chief Medical Officer | ||
| Jenny Hsieh, Chief Officer | ||
| Sunitha Lakshminarayanan, Head VP | ||
| Cynthia Pussinen, Executive Vice President - Technical Operations and Supply Chain | ||
| Kaushik Dave, President CEO, Director | ||
| Anil Kapur, Chief Commercial Officer | ||
| MS MBA, Chairman CEO | ||
| David Nicholson, Independent Director | ||
| Jehan Rowlands, Vice President and Head - Regulatory Affairs | ||
| Robert Daly, Vice President Head - Clinical Operations | ||
| Niva Almaula, Chief Business Officer | ||
| Steven BS, CFO Secretary | ||
| Steven Price, Vice President - Clinical and Commercial Strategy | ||
| Sandesh Seth, Chairman of the Board | ||
| MBA MS, Chairman CEO | ||
| Bernie PMP, Executive Management | ||
| Paul Esq, Vice Counsel | ||
| Dr MS, VP Operations | ||
| Steve OLoughlin, Principal Financial and Accounting Officer | ||
| Vijay Reddy, Vice President Clinical Development | ||
| CDavid Nicholson, Lead Independent Director | ||
| Mamata Gokhale, Vice President Global Head of Regulatory Affairs | ||
| Arun Swaminathan, Chief Officer | ||
| Elaina Haeuber, VP Operations | ||
| Ajit Shetty, Independent Director | ||
| Richard Steinhart, Director | ||
| C Nicholson, Independent Director | ||
| Mark Berger, Chief Medical Officer | ||
| David Gould, Senior Affairs | ||
| Jeffrey Chell, Independent Director | ||
| Qing Ling, Vice President Head of Radiation Sciences | ||
| Avinash MD, Chief Officer |
Actinium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Actinium Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (127.69) % | ||||
| Current Valuation | 126.8 M | ||||
| Shares Outstanding | 29.4 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 24.63 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 7.27 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actinium Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actinium Pharmaceuticals' short interest history, or implied volatility extrapolated from Actinium Pharmaceuticals options trading.
Pair Trading with Actinium Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actinium Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Actinium Stock
| 0.58 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.46 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Actinium Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Actinium Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Actinium Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Actinium Pharmaceuticals to buy it.
The correlation of Actinium Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Actinium Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Actinium Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Actinium Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Actinium Stock analysis
When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (0.95) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.